title: Cell cycle machinery: links with genesis and treatment of breast cancer.
abstract: Loss of normal growth control is a hallmark of cancer. Thus, understanding the mechanisms of tissue-specific, normal growth regulation and the changes that occur during tumorigenesis may provide insights of both diagnostic and therapeutic importance. Control of cell proliferation in the normal mammary gland is steroid hormone (estrogen and progestin)-dependent, involves complex interactions with other hormones, growth factors and cytokines and ultimately converges on activation of three proto-oncogenes (c-Myc, cyclin D1 and cyclin E1) that are rate limiting for the G1 to S phase transition during normal cell cycle progression. Mammary epithelial cell-specific overexpression of these genes induces mammary carcinoma in mice, while cyclin D1 null mice have arrested mammary gland development and are resistant to carcinoma induced by the neu/erbB2 and ras oncogenes. Furthermore, c-Myc, cyclins D1, E1 and E2 are commonly overexpressed in primary breast cancer where elevated expression is often associated with a more aggressive disease phenotype and an adverse patient outcome. This may be due in part to overexpression of these genes conferring resistance to endocrine therapies since in vitro studies provide compelling evidence that overexpression of c-Myc and to a lesser extent cyclin D1 and cyclin E1, attenuate the growth inhibitory effects of SERMS, antiestrogens and progestins in breast cancer cells. Thus, abnormal regulation of the expression of cell cycle molecules, involved in the steroidal control of cell proliferation in the mammary gland, are likely to be directly involved in the development, progression and therapeutic responsiveness of breast cancer. Furthermore, a more detailed understanding of these pathways may identify new targets for therapeutic intervention particularly in endocrine-unresponsive and endocrine-resistant disease.
authors.affiliation: Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
authors.forename: Alison J
authors.initials: AJ
authors.lastname: Butt
authors.forename: C Elizabeth
authors.initials: CE
authors.lastname: Caldon
authors.forename: Catriona M
authors.initials: CM
authors.lastname: McNeil
authors.forename: Alexander
authors.initials: A
authors.lastname: Swarbrick
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Musgrove
authors.forename: Robert L
authors.initials: RL
authors.lastname: Sutherland
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000235:genetics* / Q000628:therapy*; D002453:Cell Cycle / Q000235:genetics*; D018844:Cyclin-Dependent Kinases / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor / Q000502:physiology; D006801:Humans; D008954:Models, Biological; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D009857:Oncogenes / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D018844:Cyclin-Dependent Kinases